Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 2/20 | 0.37 |
| ▸ | HTR1B | P28222 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | AOC2 | O75106 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16613903 | 0.81 | HDAC1 (0.42) | HDAC1HDAC2KCNA3LMNATBXA2R | |
| SCHEMBL16613936 | 0.81 | ALDH1A1 (0.42) | HDAC1HDAC2KCNA3LTA4HTAAR1 | |
| SCHEMBL10076987 | 0.81 | LMNA (0.41) | HDAC1HDAC2KCNA3LTA4HLMNA | |
| Potassium Ion SCHEMBL17421828 | 0.77 | HDAC1 (0.36) | HDAC1HDAC2KCNA3TBXA2RTAAR1 | |
| SCHEMBL20749935 | 0.77 | HDAC1 (0.40) | HDAC1HDAC2KCNA3TBXA2RALDH1A1 | |
| SCHEMBL17429872 | 0.75 | HDAC1 (0.38) | HDAC1HDAC2KCNA3TBXA2RALDH1A1 | |
| SCHEMBL12956629 | 0.74 | KCNA3 (0.46) | HDAC1HDAC2KCNA3LTA4HHTR1B | |
| SCHEMBL20441229 | 0.74 | TBXA2R (0.39) | HDAC1HDAC2LTA4HTBXA2R | |
| SCHEMBL2280790 | 0.73 | ALDH1A1 (0.50) | HDAC1HDAC2KCNA3LTA4HLMNA | |
| SCHEMBL14227125 | 0.71 | KCNA3 (0.43) | HDAC1HDAC2KCNA3LTA4HHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017189953-A1 | POLY(KETALS) AND RELATED COMPOSITIONS AND METHODS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-11-02 | — | — | WO | disclosed |
| US-9670234-B2 | Metal-catalyzed asymmetric 1,4-conjugate addition of vinylboron compounds to 2-substituted-4-oxy-cyclopent-2-en-1-ones yielding prostaglandins and prostaglandin analogs | SCINOPHARM TAIWAN, LTD. (TW) | 2017-06-06 | — | — | US | disclosed |
| US-20160237056-A1 | NOVEL SYNTHESIS ROUTES FOR PROSTAGLANDINS AND PROSTAGLANDIN INTERMEDIATES USING METATHESIS | PATHEON API SERVICES INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160237056-A1 | NOVEL SYNTHESIS ROUTES FOR PROSTAGLANDINS AND PROSTAGLANDIN INTERMEDIATES USING METATHESIS | PATHEON API SERVICES INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160009740-A1 | METAL-CATALYZED ASYMMETRIC 1,4-CONJUGATE ADDITION OF VINYLBORON COMPOUNDS TO 2-SUBSTITUTED-4-OXY-CYCLOPENT-2-EN-1-ONES YIELDING PROSTAGLANDINS AND PROSTAGLANDIN ANALOGS | SCINOPHARM TAIWAN, LTD. (TW) | 2016-01-14 | — | — | US | disclosed |
| WO-2015048736-A1 | NOVEL SYNTHESIS ROUTES FOR PROSTAGLANDINS AND PROSTAGLANDIN INTERMEDIATES USING METATHESIS | IRIX PHARMACEUTICALS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| US-20130131106-A1 | BIFUNCTIONAL RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237056-A1 | NOVEL SYNTHESIS ROUTES FOR PROSTAGLANDINS AND PROSTAGLANDIN INTERMEDIATES USING METATHESIS | PTGES, PTGIS, PTGES2 | HDAC1 4768/4885HDAC2 4261/4885KCNA3 2690/4885 |
| US-20160009740-A1 | METAL-CATALYZED ASYMMETRIC 1,4-CONJUGATE ADDITION OF VINYLBORON COMPOUNDS TO 2-SUBSTITUTED-4-OXY-CYCLOPENT-2-EN-1-ONES YIELDING PROSTAGLANDINS AND PROSTAGLANDIN ANALOGS | PTGIS, PTGER1, PTGS1 | HDAC1 4196/4885HDAC2 2269/4885KCNA3 992/4885 |
| US-20130131106-A1 | BIFUNCTIONAL RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | ROCK2, ROCK1, RHOA | HDAC1 897/4885HDAC2 1086/4885KCNA3 4312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.